Araştırma Makalesi

Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort

Cilt: 36 Sayı: 2026 28 Eylül 2026
PDF İndir
EN TR

Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort

Öz

Aim: Previous studies have largely focused on delays and non-adherence among patients assigned BI-RADS 0 on mammography. However, data describing diagnostic outcomes among patients who return for supplemental imaging (SI), particularly in tertiary care settings, remain limited. The aim of this study was to evaluate follow-up patterns after BI-RADS 0 mammography and to assess diagnostic outcomes, including BI-RADS reassignment, biopsy rates, and malignancy yield, among patients who completed SI.
Materials and Methods: Mammograms performed at our institution between November 2023 and April 2025 were retrospectively reviewed. Patients assigned BI-RADS 0 and recalled for SI were included. Time to SI, post-imaging BI-RADS categories, biopsy performance, and pathology outcomes were analyzed. Due to skewed distributions, time-related variables were summarized primarily using medians, and appropriate non-parametric statistical tests were applied.
Results: Of 780 patients assigned BI-RADS 0, 672 (86.15%) returned for SI. Most patients completed SI promptly, with 95.4% returning within 60 days. Following SI, the majority were reassigned BI-RADS 1–3, while 9.68% were categorized as BI-RADS 4 or 5. Biopsy was performed in 9.67% of patients, and malignancy was identified in 1.49% of the overall cohort. All patients with BI-RADS 5 findings and a subset of those with BI-RADS 4 findings were diagnosed with malignancy. Patients with malignant pathology underwent biopsy sooner than those with benign findings, reflecting appropriate clinical prioritization.
Conclusions: In this tertiary care cohort, most BI-RADS 0 recalls were resolved rapidly with SI, and only a minority required biopsy. Malignancy rates were consistent with expected BI-RADS-associated risks, providing real-world reassurance regarding the efficiency and clinical appropriateness of diagnostic evaluation after BI-RADS 0 assessments.

Anahtar Kelimeler

Biopsy, BI-RADS 0, Foolow-up, Mammography, Supplemental Imaging

Destekleyen Kurum

None

Etik Beyan

Patients were evaluated after approval was obtained from the Gaziantep City Hospital Institutional Review Board (Ethics Committee; Decision No: 117/2025, Date: 15-01-2025). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Teşekkür

None

Kaynakça

  1. 1. Platt S, Montgomery GH, Schnur JB, Margolies L. BI-RADS-0 screening mammography: risk factors that prevent or delay follow-up time to diagnostic evaluation. J Am Coll Radiol. 2022;19(11):1262-1268.
  2. 2. Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, et al. Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res (Phila). 2014;7(10):993-1001.
  3. 3. Kopans DB. Screening for breast cancer and mortality reduction among women 40-49 years of age. Cancer. 1994;74(S1):311-322.
  4. 4. Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong YN, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330-339.
  5. 5. Anggondowati T, Ganti AK, Islam KM. Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database. Transl Lung Cancer Res. 2020;9(4):1202.
  6. 6. Rosenberg RD, Haneuse SJ, Geller BM, Buist DS, Miglioretti DL, Brenner RJ, et al. Timeliness of follow-up after abnormal screening mammogram: variability of facilities. Radiology. 2011;261(2):404-413.
  7. 7. Sickles EA. ACR BI-RADS Atlas: Breast Imaging Reporting and Data System. Reston (VA): American College of Radiology; 2013.
  8. 8. Miller JW, Hanson V, Johnson GD, Royalty JE, Richardson LC. From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program. Cancer. 2014;120(S16):2549-2556.
  9. 9. Allen JD, Shelton RC, Harden E, Goldman RE. Follow-up of abnormal screening mammograms among low-income ethnically diverse women: findings from a qualitative study. Patient Educ Couns. 2008;72(2):283-292.
  10. 10. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis: summary document. Oncol Clin Pract. 2008;4(2):74-86.

Kaynak Göster

APA
Kaya, M., Konukoğlu, O., & Arslan, B. C. (2026). Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort. Genel Tıp Dergisi, 36(2026), 1-7. https://doi.org/10.54005/geneltip.1836959
AMA
1.Kaya M, Konukoğlu O, Arslan BC. Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort. Genel Tıp Derg. 2026;36(2026):1-7. doi:10.54005/geneltip.1836959
Chicago
Kaya, Murat, Osman Konukoğlu, ve Barış Can Arslan. 2026. “Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort”. Genel Tıp Dergisi 36 (2026): 1-7. https://doi.org/10.54005/geneltip.1836959.
EndNote
Kaya M, Konukoğlu O, Arslan BC (01 Eylül 2026) Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort. Genel Tıp Dergisi 36 2026 1–7.
IEEE
[1]M. Kaya, O. Konukoğlu, ve B. C. Arslan, “Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort”, Genel Tıp Derg, c. 36, sy 2026, ss. 1–7, Eyl. 2026, doi: 10.54005/geneltip.1836959.
ISNAD
Kaya, Murat - Konukoğlu, Osman - Arslan, Barış Can. “Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort”. Genel Tıp Dergisi 36/2026 (01 Eylül 2026): 1-7. https://doi.org/10.54005/geneltip.1836959.
JAMA
1.Kaya M, Konukoğlu O, Arslan BC. Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort. Genel Tıp Derg. 2026;36:1–7.
MLA
Kaya, Murat, vd. “Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort”. Genel Tıp Dergisi, c. 36, sy 2026, Eylül 2026, ss. 1-7, doi:10.54005/geneltip.1836959.
Vancouver
1.Murat Kaya, Osman Konukoğlu, Barış Can Arslan. Diagnostic Follow-Up of BI-RADS 0: Rates of Biopsy and Malignancy in a Single-Center Cohort. Genel Tıp Derg. 01 Eylül 2026;36(2026):1-7. doi:10.54005/geneltip.1836959